|
[1]
|
Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinoma
Annals of Surgical Oncology,
2024
DOI:10.1245/s10434-024-16245-1
|
|
|
|
|
[2]
|
Role of myeloid-derived suppressor cells in tumor recurrence
Cancer and Metastasis Reviews,
2023
DOI:10.1007/s10555-023-10079-1
|
|
|
|
|
[3]
|
Role of myeloid-derived suppressor cells in tumor recurrence
Cancer and Metastasis Reviews,
2023
DOI:10.1007/s10555-023-10079-1
|
|
|
|
|
[4]
|
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
Journal for ImmunoTherapy of Cancer,
2023
DOI:10.1136/jitc-2022-006589
|
|
|
|
|
[5]
|
Role of myeloid-derived suppressor cells in tumor recurrence
Cancer and Metastasis Reviews,
2023
DOI:10.1007/s10555-023-10079-1
|
|
|
|
|
[6]
|
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
Journal for ImmunoTherapy of Cancer,
2023
DOI:10.1136/jitc-2022-006589
|
|
|
|
|
[7]
|
The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer
Technology in Cancer Research & Treatment,
2022
DOI:10.1177/15330338221142472
|
|
|
|
|
[8]
|
The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer
Technology in Cancer Research & Treatment,
2022
DOI:10.1177/15330338221142472
|
|
|
|
|
[9]
|
The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer
Technology in Cancer Research & Treatment,
2022
DOI:10.1177/15330338221142472
|
|
|
|
|
[10]
|
Role of myeloid-derived suppressor cells in metastasis
Cancer and Metastasis Reviews,
2021
DOI:10.1007/s10555-020-09947-x
|
|
|
|
|
[11]
|
Role of myeloid-derived suppressor cells in metastasis
Cancer and Metastasis Reviews,
2021
DOI:10.1007/s10555-020-09947-x
|
|
|
|
|
[12]
|
Role of myeloid-derived suppressor cells in metastasis
Cancer and Metastasis Reviews,
2021
DOI:10.1007/s10555-020-09947-x
|
|
|
|
|
[13]
|
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model
Cancer Immunology, Immunotherapy,
2020
DOI:10.1007/s00262-020-02605-9
|
|
|
|
|
[14]
|
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
Frontiers in Immunology,
2020
DOI:10.3389/fimmu.2020.01680
|
|
|
|
|
[15]
|
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Clinical and Translational Medicine,
2019
DOI:10.1186/s40169-019-0226-9
|
|
|
|
|
[16]
|
Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches
Cancers,
2019
DOI:10.3390/cancers11111627
|
|
|
|
|
[17]
|
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Clinical and Translational Medicine,
2019
DOI:10.1186/s40169-019-0226-9
|
|
|
|
|
[18]
|
Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches
Cancers,
2019
DOI:10.3390/cancers11111627
|
|
|
|
|
[19]
|
Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells – is a new era coming?
Critical Reviews in Clinical Laboratory Sciences,
2018
DOI:10.1080/10408363.2018.1477729
|
|
|
|
|
[20]
|
Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy
International Reviews of Immunology,
2017
DOI:10.1080/08830185.2017.1363199
|
|
|
|
|
[21]
|
T-cell programming in pancreatic adenocarcinoma: a review
Cancer Gene Therapy,
2017
DOI:10.1038/cgt.2016.66
|
|
|
|
|
[22]
|
Myeloid-Derived Suppressor Cells and Cancer
SpringerBriefs in Immunology,
2016
DOI:10.1007/978-3-319-26821-7_1
|
|
|
|
|
[23]
|
Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
Seminars in Immunology,
2016
DOI:10.1016/j.smim.2016.03.018
|
|
|
|
|
[24]
|
A clinical and biological perspective of human myeloid-derived suppressor cells in cancer
Cellular and Molecular Life Sciences,
2016
DOI:10.1007/s00018-016-2278-y
|
|
|
|
|
[25]
|
Role of immune cells in pancreatic cancer from bench to clinical application
Medicine,
2016
DOI:10.1097/MD.0000000000005541
|
|
|
|
|
[26]
|
Bisphosphonates as potential adjuvants for patients with cancers of the digestive system
World Journal of Gastroenterology,
2016
DOI:10.3748/wjg.v22.i3.906
|
|
|
|
|
[27]
|
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,
2016
DOI:10.1016/j.bbcan.2015.08.001
|
|
|
|
|
[28]
|
Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer
Journal of Surgical Oncology,
2015
DOI:10.1002/jso.23816
|
|
|
|
|
[29]
|
Selective efficacy of zoledronic acid on metastasis in a patient‐derived orthotopic xenograph (PDOX) nude‐mouse model of human pancreatic cancer
Journal of Surgical Oncology,
2015
DOI:10.1002/jso.23816
|
|
|
|
|
[30]
|
Myeloid-derived suppressor cell heterogeneity in human cancers
Annals of the New York Academy of Sciences,
2014
DOI:10.1111/nyas.12469
|
|
|
|
|
[31]
|
Stromal reengineering to treat pancreas cancer
Carcinogenesis,
2014
DOI:10.1093/carcin/bgu115
|
|
|
|
|
[32]
|
Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation
British Journal of Cancer,
2014
DOI:10.1038/bjc.2014.385
|
|
|
|
|
[33]
|
Signaling pathways involved in MDSC regulation
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,
2014
DOI:10.1016/j.bbcan.2014.04.003
|
|
|
|
|
[34]
|
Endoscopic Submucosal Dissection for Gastric Neoplasm at an Outpatient Clinic: Efficacy and Safety
Clinical Endoscopy,
2014
DOI:10.5946/ce.2014.47.6.473
|
|
|
|
|
[35]
|
Molecular Pathways: Myeloid Complicity in Cancer
Clinical Cancer Research,
2014
DOI:10.1158/1078-0432.CCR-13-0866
|
|
|
|
|
[36]
|
Myeloid‐derived suppressor cell heterogeneity in human cancers
Annals of the New York Academy of Sciences,
2014
DOI:10.1111/nyas.12469
|
|
|
|